BioCentury
ARTICLE | Clinical News

NuQ V001 regulatory update

April 25, 2016 7:00 AM UTC

VolitionRx received CE Mark approval for NuQ T003 and NuQ V001 biomarker assays to detect colorectal cancer. The blood-based tests use the company’s Nucleosomics technology, which identifies and meas...